Soren Lehmann

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: HAEMATOLOGICA. 2021;106(10):2566-2577

Combinatorial molecule screening identified a novel diterpene and the BET inhibitor CPI-203 as differentiation inducers of primary acute myeloid leukemia cells.

Hultmark S; Baudet A; Schmiderer L; Prabhala P; Palma-Tortosa S; Sandén C; Fioretos T; Sasidharan R; Larsson C; Lehmann S; Juliusson G; Ek F; Magnusson M
Article: LEUKEMIA & LYMPHOMA. 2021;62(8):1973-1981

Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based study.

Rosso A; Juliusson G; Lorenz F; Lehmann S; Derolf Å; Deneberg S; Jädersten M; Antunovic P; Cammenga J; Möllgård L; Wennström L; Ölander E; Ehinger M; Fogelstrand L; Höglund M; Lazarevic VL
Article: GENES CHROMOSOMES & CANCER. 2021;60(6):426-433

Clinical and genomic characterization of patients diagnosed with the provisional entity acute myeloid leukemia with BCR-ABL1, a Swedish population-based study.

Orsmark-Pietras C; Landberg N; Lorenz F; Uggla B; Höglund M; Lehmann S; Derolf Å; Deneberg S; Antunovic P; Cammenga J; Möllgård L; Wennström L; Lilljebjörn H; Rissler M; Fioretos T; Lazarevic VL
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2021;96(5):580-588

The transcriptome-wide landscape of molecular subtype-specific mRNA expression profiles in acute myeloid leukemia.

Mou T; Pawitan Y; Stahl M; Vesterlund M; Deng W; Jafari R; Bohlin A; Österroos A; Siavelis L; Bäckvall H; Erkers T; Kiviluoto S; Seashore-Ludlow B; Östling P; Orre LM; Kallioniemi O; Lehmann S; Lehtiö J; Vu TN
Article: BLOOD ADVANCES. 2021;5(4):1003-1016

Challenging conventional karyotyping by next-generation karyotyping in 281 intensively treated patients with AML.

Mareschal S; Palau A; Lindberg J; Ruminy P; Nilsson C; Bengtzén S; Engvall M; Eriksson A; Neddermeyer A; Marchand V; Jansson M; Björklund M; Jardin F; Rantalainen M; Lennartsson A; Cavelier L; Grönberg H; Lehmann S
Article: NATURE COMMUNICATIONS. 2021;12(1):1054

Biological and therapeutic implications of a unique subtype of NPM1 mutated AML.

Mer AS; Heath EM; Madani Tonekaboni SA; Dogan-Artun N; Nair SK; Murison A; Garcia-Prat L; Shlush L; Hurren R; Voisin V; Bader GD; Nislow C; Rantalainen M; Lehmann S; Gower M; Guidos CJ; Lupien M; Dick JE; Minden MD; Schimmer AD; Haibe-Kains B
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;192(3):474-483

Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study.

Moreno Berggren D; Kjellander M; Backlund E; Engvall M; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellström-Lindberg E; Jädersten M; Ungerstedt J; Ejerblad E
Article: BLOOD. 2020;136(3):339-352

AML displays increased CTCF occupancy associated with aberrant gene expression and transcription factor binding.

Mujahed H; Miliara S; Neddermeyer A; Bengtzén S; Nilsson C; Deneberg S; Cordeddu L; Ekwall K; Lennartsson A; Lehmann S
Article: CLINICAL CANCER RESEARCH. 2020;26(14):3597-3607

RNA Splicing Alterations Induce a Cellular Stress Response Associated with Poor Prognosis in Acute Myeloid Leukemia.

Anande G; Deshpande NP; Mareschal S; Batcha AMN; Hampton HR; Herold T; Lehmann S; Wilkins MR; Wong JWH; Unnikrishnan A; Pimanda JE
Article: GENOME BIOLOGY. 2020;21(1):153

Allele-specific DNA methylation is increased in cancers and its dense mapping in normal plus neoplastic cells increases the yield of disease-associated regulatory SNPs.

Do C; Dumont ELP; Salas M; Castano A; Mujahed H; Maldonado L; Singh A; DaSilva-Arnold SC; Bhagat G; Lehman S; Christiano AM; Madhavan S; Nagy PL; Green PHR; Feinman R; Trimble C; Illsley NP; Marder K; Honig L; Monk C; Goy A; Chow K; Goldlust S; Kaptain G; Siegel D; Tycko B
Article: BLOOD CANCER JOURNAL. 2020;10(6):67

Integrated transcriptomic and genomic analysis improves prediction of complete remission and survival in elderly patients with acute myeloid leukemia.

Österroos A; Björklund M; Eriksson A; Lindberg J; Nilsson C; Mareschal S; Rantalainen M; Grönberg H; Lehmann S
Article: BLOOD ADVANCES. 2020;4(6):1094-1101

The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting.

Juliusson G; Jädersten M; Deneberg S; Lehmann S; Möllgård L; Wennström L; Antunovic P; Cammenga J; Lorenz F; Ölander E; Lazarevic VL; Höglund M
Article: EMBO MOLECULAR MEDICINE. 2020;12(3):e10419

Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy.

Rudd SG; Tsesmetzis N; Sanjiv K; Paulin CB; Sandhow L; Kutzner J; Hed Myrberg I; Bunten SS; Axelsson H; Zhang SM; Rasti A; Mäkelä P; Coggins SA; Tao S; Suman S; Branca RM; Mermelekas G; Wiita E; Lee S; Walfridsson J; Schinazi RF; Kim B; Lehtiö J; Rassidakis GZ; Pokrovskaja Tamm K; Warpman-Berglund U; Heyman M; Grandér D; Lehmann S; Lundbäck T; Qian H; Henter J-I; Schaller T; Helleday T; Herold N
Article: JOURNAL OF CLINICAL ONCOLOGY. 2019;37(29):2632-2642

Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts.

Angenendt L; Röllig C; Montesinos P; Martínez-Cuadrón D; Barragan E; García R; Botella C; Martínez P; Ravandi F; Kadia T; Kantarjian HM; Cortes J; Juliusson G; Lazarevic V; Höglund M; Lehmann S; Recher C; Pigneux A; Bertoli S; Dumas P-Y; Dombret H; Preudhomme C; Micol J-B; Terré C; Ráčil Z; Novák J; Žák P; Wei AH; Tiong IS; Wall M; Estey E; Shaw C; Exeler R; Wagenführ L; Stölzel F; Thiede C; Stelljes M; Lenz G; Mikesch J-H; Serve H; Ehninger G; Berdel WE; Kramer M; Krug U; Schliemann C
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2019;25(9):1770-1778

Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting.

Nilsson C; Hulegårdh E; Garelius H; Möllgård L; Brune M; Wahlin A; Lenhoff S; Frödin U; Remberger M; Höglund M; Juliusson G; Stockelberg D; Lehmann S
Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2018;110(10):1094-1101

Development and Validation of a Novel RNA Sequencing-Based Prognostic Score for Acute Myeloid Leukemia.

Wang M; Lindberg J; Klevebring D; Nilsson C; Lehmann S; Grönberg H; Rantalainen M
Article: SCIENTIFIC REPORTS. 2018;8(1):11293

Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia.

Hornung R; Jurinovic V; Batcha AMN; Bamopoulos SA; Rothenberg-Thurley M; Amler S; Sauerland MC; Berdel WE; Wörmann BJ; Bohlander SK; Braess J; Hiddemann W; Lehmann S; Mareschal S; Spiekermann K; Metzeler KH; Herold T; Boulesteix A-L
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2018;181(5):614-627

Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register.

Moreno Berggren D; Folkvaljon Y; Engvall M; Sundberg J; Lambe M; Antunovic P; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellström-Lindberg E; Jädersten M; Ejerblad E
Article: JOURNAL OF HEMATOLOGY & ONCOLOGY. 2018;11(1):52

Expression levels of long non-coding RNAs are prognostic for AML outcome.

Mer AS; Lindberg J; Nilsson C; Klevebring D; Wang M; Grönberg H; Lehmann S; Rantalainen M
Article: FREE RADICAL BIOLOGY AND MEDICINE. 2018;117:247-257

Selenite and methylseleninic acid epigenetically affects distinct gene sets in myeloid leukemia: A genome wide epigenetic analysis.

Khalkar P; Ali HA; Codó P; Argelich ND; Martikainen A; Arzenani MK; Lehmann S; Walfridsson J; Ungerstedt J; Fernandes AP
Article: LEUKEMIA. 2017;31(10):2029-2036

Validation of risk stratification models in acute myeloid leukemia using sequencing-based molecular profiling.

Wang M; Lindberg J; Klevebring D; Nilsson C; Mer AS; Rantalainen M; Lehmann S; Grönberg H
Article: CANCER IMMUNOLOGY RESEARCH. 2017;5(8):654-665

Ex Vivo Expanded Adaptive NK Cells Effectively Kill Primary Acute Lymphoblastic Leukemia Cells.

Liu LL; Béziat V; Oei VYS; Pfefferle A; Schaffer M; Lehmann S; Hellström-Lindberg E; Söderhäll S; Heyman M; Grandér D; Malmberg K-J
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2017;98(5):493-500

Incidence and prognostic significance of isolated trisomies in adult acute myeloid leukemia: A population-based study from the Swedish AML registry.

Lazarevic VL; Rosso A; Juliusson G; Antunovic P; Derolf ÅR; Deneberg S; Möllgård L; Uggla B; Wennström L; Wahlin A; Höglund M; Lehmann S; Johansson B
Article: LEUKEMIA. 2017;31(5):1108-1116

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.

Ilander M; Olsson-Strömberg U; Schlums H; Guilhot J; Brück O; Lähteenmäki H; Kasanen T; Koskenvesa P; Söderlund S; Höglund M; Markevärn B; Själander A; Lotfi K; Dreimane A; Lübking A; Holm E; Björeman M; Lehmann S; Stenke L; Ohm L; Gedde-Dahl T; Majeed W; Ehrencrona H; Koskela S; Saussele S; Mahon F-X; Porkka K; Hjorth-Hansen H; Bryceson YT; Richter J; Mustjoki S
Article: ONCOTARGET. 2017;8(17):28812-28825

Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease.

Tobiasson M; Abdulkadir H; Lennartsson A; Katayama S; Marabita F; De Paepe A; Karimi M; Krjutskov K; Einarsdottir E; Grövdal M; Jansson M; Ben Azenkoud A; Corddedu L; Lehmann S; Ekwall K; Kere J; Hellström-Lindberg E; Ungerstedt J
Article: BLOOD. 2017;129(7):e13-e25

Cancer-specific changes in DNA methylation reveal aberrant silencing and activation of enhancers in leukemia.

Qu Y; Siggens L; Cordeddu L; Gaidzik VI; Karlsson K; Bullinger L; Döhner K; Ekwall K; Lehmann S; Lennartsson A
Article: NATURE MEDICINE. 2017;23(2):256-263

Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.

Herold N; Rudd SG; Ljungblad L; Sanjiv K; Myrberg IH; Paulin CBJ; Heshmati Y; Hagenkort A; Kutzner J; Page BDG; Calderón-Montaño JM; Loseva O; Jemth A-S; Bulli L; Axelsson H; Tesi B; Valerie NCK; Höglund A; Bladh J; Wiita E; Sundin M; Uhlin M; Rassidakis G; Heyman M; Tamm KP; Warpman-Berglund U; Walfridsson J; Lehmann S; Grandér D; Lundbäck T; Kogner P; Henter J-I; Helleday T; Schaller T
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2016;174(1):117-126

Anti-leukaemic effects induced by APR-246 are dependent on induction of oxidative stress and the NFE2L2/HMOX1 axis that can be targeted by PI3K and mTOR inhibitors in acute myeloid leukaemia cells.

Ali D; Mohammad DK; Mujahed H; Jonson-Videsäter K; Nore B; Paul C; Lehmann S
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2015;90(9):800-805

Prognostic significance of high hyperdiploid and triploid/tetraploid adult acute myeloid leukemia.

Lazarevic V; Rosso A; Juliusson G; Antunovic P; Rangert-Derolf Å; Lehmann S; Möllgård L; Uggla B; Wennström L; Wahlin A; Höglund M; Johansson B
Article: EXPERIMENTAL HEMATOLOGY. 2015;43(8):609-624

Epigenetic aberrations in acute myeloid leukemia: Early key events during leukemogenesis.

Eriksson A; Lennartsson A; Lehmann S
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2015;94(5):419-423

Failure matters: unsuccessful cytogenetics and unperformed cytogenetics are associated with a poor prognosis in a population-based series of acute myeloid leukaemia.

Lazarevic V; Hörstedt A-S; Johansson B; Antunovic P; Billström R; Derolf Å; Lehmann S; Möllgård L; Peterson S; Stockelberg D; Uggla B; Vennström L; Wahlin A; Höglund M; Juliusson G
Article: LEUKEMIA. 2015;29(5):1084-1091

Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet.

Lengfelder E; Lo-Coco F; Ades L; Montesinos P; Grimwade D; Kishore B; Ramadan SM; Pagoni M; Breccia M; Huerta AJG; Nloga AM; González-Sanmiguel JD; Schmidt A; Lambert J-F; Lehmann S; Di Bona E; Cassinat B; Hofmann W-K; Görlich D; Sauerland M-C; Fenaux P; Sanz M; European LeukemiaNet
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2015;90(3):208-214

Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: a report from the Swedish Acute Leukemia Registry.

Hulegårdh E; Nilsson C; Lazarevic V; Garelius H; Antunovic P; Rangert Derolf Å; Möllgård L; Uggla B; Wennström L; Wahlin A; Höglund M; Juliusson G; Stockelberg D; Lehmann S
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2014;371(26):2477-2487

Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence.

Genovese G; Kähler AK; Handsaker RE; Lindberg J; Rose SA; Bakhoum SF; Chambert K; Mick E; Neale BM; Fromer M; Purcell SM; Svantesson O; Landén M; Höglund M; Lehmann S; Gabriel SB; Moran JL; Lander ES; Sullivan PF; Sklar P; Grönberg H; Hultman CM; McCarroll SA
Article: EPIGENETICS. 2014;9(8):1108-1119

Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by DNMT3A mutational status and associated with predominant hypomethylation of HOX genes.

Qu Y; Lennartsson A; Gaidzik VI; Deneberg S; Karimi M; Bengtzén S; Höglund M; Bullinger L; Döhner K; Lehmann S
Article: BMC GENOMICS. 2014;15(1):487

Relationship between genome and epigenome--challenges and requirements for future research.

Almouzni G; Altucci L; Amati B; Ashley N; Baulcombe D; Beaujean N; Bock C; Bongcam-Rudloff E; Bousquet J; Braun S; Bressac-de Paillerets B; Bussemakers M; Clarke L; Conesa A; Estivill X; Fazeli A; Grgurević N; Gut I; Heijmans BT; Hermouet S; Houwing-Duistermaat J; Iacobucci I; Ilaš J; Kandimalla R; Krauss-Etschmann S; Lasko P; Lehmann S; Lindroth A; Majdič G; Marcotte E; Martinelli G; Martinet N; Meyer E; Miceli C; Mills K; Moreno-Villanueva M; Morvan G; Nickel D; Niesler B; Nowacki M; Nowak J; Ossowski S; Pelizzola M; Pochet R; Potočnik U; Radwanska M; Raes J; Rattray M; Robinson MD; Roelen B; Sauer S; Schinzer D; Slagboom E; Spector T; Stunnenberg HG; Tiligada E; Torres-Padilla M-E; Tsonaka R; Van Soom A; Vidaković M; Widschwendter M
Article: EPIGENETICS. 2014;9(6):910-917

microRNA-34b/c on chromosome 11q23 is aberrantly methylated in chronic lymphocytic leukemia.

Deneberg S; Kanduri M; Ali D; Bengtzen S; Karimi M; Qu Y; Kimby E; Mansouri L; Rosenquist R; Lennartsson A; Lehmann S
Article: BLOOD. 2014;123(17):e79-e89

Analysis of the DNA methylome and transcriptome in granulopoiesis reveals timed changes and dynamic enhancer methylation.

Rönnerblad M; Andersson R; Olofsson T; Douagi I; Karimi M; Lehmann S; Hoof I; de Hoon M; Itoh M; Nagao-Sato S; Kawaji H; Lassmann T; Carninci P; Hayashizaki Y; Forrest ARR; Sandelin A; Ekwall K; Arner E; Lennartsson A; FANTOM consortium
Article: BLOOD CANCER JOURNAL. 2014;4(2):e188

Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience.

Lazarevic V; Hörstedt A-S; Johansson B; Antunovic P; Billström R; Derolf A; Hulegårdh E; Lehmann S; Möllgård L; Nilsson C; Peterson S; Stockelberg D; Uggla B; Wennström L; Wahlin A; Höglund M; Juliusson G
Article: BLOOD. 2013;122(7):1284-1292

Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry.

Höglund M; Sandin F; Hellström K; Björeman M; Björkholm M; Brune M; Dreimane A; Ekblom M; Lehmann S; Ljungman P; Malm C; Markevärn B; Myhr-Eriksson K; Ohm L; Olsson-Strömberg U; Själander A; Wadenvik H; Simonsson B; Stenke L; Richter J
Article: LEUKEMIA & LYMPHOMA. 2013;54(4):843-850

Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies.

Daneshmanesh AH; Porwit A; Hojjat-Farsangi M; Jeddi-Tehrani M; Tamm KP; Grandér D; Lehmann S; Norin S; Shokri F; Rabbani H; Mellstedt H; Österborg A
Article: JOURNAL OF CLINICAL ONCOLOGY. 2012;30(29):3633-3639

Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer.

Lehmann S; Bykov VJN; Ali D; Andrén O; Cherif H; Tidefelt U; Uggla B; Yachnin J; Juliusson G; Moshfegh A; Paul C; Wiman KG; Andersson P-O
Article: HAEMATOLOGICA. 2012;97(9):1380-1388

A critical appraisal of tools available for monitoring epigenetic changes in clinical samples from patients with myeloid malignancies.

Grønbæk K; Müller-Tidow C; Perini G; Lehmann S; Bach Treppendahl M; Mills K; Plass C; Schlegelberger B; European Genomics and Epigenomics Study on MDS and
Article: BLOOD. 2011;118(20):5573-5582

Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks.

Deneberg S; Guardiola P; Lennartsson A; Qu Y; Gaidzik V; Blanchet O; Karimi M; Bengtzén S; Nahi H; Uggla B; Tidefelt U; Höglund M; Paul C; Ekwall K; Döhner K; Lehmann S
Article: CANCER. 2011;117(18):4238-4246

Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: real-world population-based data from the Swedish Acute Leukemia Registry 1997-2006.

Juliusson G; Karlsson K; Lazarevic VL; Wahlin A; Brune M; Antunovic P; Derolf A; Hägglund H; Karbach H; Lehmann S; Möllgård L; Stockelberg D; Hallböök H; Höglund M; Swedish Acute Leukemia Registry Group, the Swedish
Article: LEUKEMIA. 2011;25(7):1128-1134

Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry.

Lehmann S; Ravn A; Carlsson L; Antunovic P; Deneberg S; Möllgård L; Derolf AR; Stockelberg D; Tidefelt U; Wahlin A; Wennström L; Höglund M; Juliusson G
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2011;86(3):206-215

APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells.

Ali D; Jönsson-Videsäter K; Deneberg S; Bengtzén S; Nahi H; Paul C; Lehmann S
Article: LEUKEMIA. 2010;24(5):932-941

Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia.

Deneberg S; Grövdal M; Karimi M; Jansson M; Nahi H; Corbacioglu A; Gaidzik V; Döhner K; Paul C; Ekström TJ; Hellström-Lindberg E; Lehmann S
Article: CANCER LETTERS. 2009;282(1):116-123

Selenite is a potent cytotoxic agent for human primary AML cells.

Olm E; Jönsson-Videsäter K; Ribera-Cortada I; Fernandes AP; Eriksson LC; Lehmann S; Rundlöf A-K; Paul C; Björnstedt M
Article: HAEMATOLOGICA. 2009;94(9):1301-1306

Single nucleotide polymorphism genomic arrays analysis of t(8;21) acute myeloid leukemia cells.

Akagi T; Shih L-Y; Ogawa S; Gerss J; Moore SR; Schreck R; Kawamata N; Liang D-C; Sanada M; Nannya Y; Deneberg S; Zachariadis V; Nordgren A; Song JH; Dugas M; Lehmann S; Koeffler HP
Article: BLOOD. 2009;113(18):4179-4187

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.

Juliusson G; Antunovic P; Derolf A; Lehmann S; Möllgård L; Stockelberg D; Tidefelt U; Wahlin A; Höglund M
Article: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2008;62(3):439-448

The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia.

Möllgård L; Deneberg S; Nahi H; Bengtzen S; Jonsson-Videsäter K; Fioretos T; Andersson A; Paul C; Lehmann S
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2008;141(4):445-453

Mutated and non-mutated TP53 as targets in the treatment of leukaemia.

Nahi H; Selivanova G; Lehmann S; Möllgård L; Bengtzen S; Concha H; Svensson A; Wiman KG; Merup M; Paul C
Article: CANCER. 2008;112(6):1296-1305

Molecular allelokaryotyping of early-stage, untreated chronic lymphocytic leukemia.

Lehmann S; Ogawa S; Raynaud SD; Sanada M; Nannya Y; Ticchioni M; Bastard C; Kawamata N; Koeffler HP
Article: LEUKEMIA & LYMPHOMA. 2008;49(3):508-516

Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia.

Nahi H; Lehmann S; Bengtzen S; Jansson M; Möllgård L; Paul C; Merup M
Article: THERAPEUTIC DRUG MONITORING. 2007;29(5):626-631

Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia.

Löfgren C; Lehmann S; Jönsson-Videsäter K; Möllgård L; Linder O; Tidefelt U; Hassan M; Paul C
Article: LEUKEMIA. 2007;21(9):1931-1936

Common deleted genes in the 5q- syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice.

Lehmann S; O'Kelly J; Raynaud S; Funk SE; Sage EH; Koeffler HP
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2006;132(2):230-236

PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion.

Nahi H; Merup M; Lehmann S; Bengtzen S; Möllgård L; Selivanova G; Wiman KG; Paul C
Article: NATURE MEDICINE. 2005;11(6):630-637

Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia.

Castor A; Nilsson L; Astrand-Grundström I; Buitenhuis M; Ramirez C; Anderson K; Strömbeck B; Garwicz S; Békássy AN; Schmiegelow K; Lausen B; Hokland P; Lehmann S; Juliusson G; Johansson B; Jacobsen SEW
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2004;127(3):285-291

Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion.

Nahi H; Lehmann S; Mollgard L; Bengtzen S; Selivanova G; Wiman KG; Paul C; Merup M
Article: BIOCHEMICAL PHARMACOLOGY. 2002;63(10):1875-1884

Drug-resistant human lung cancer cells are more sensitive to selenium cytotoxicity. Effects on thioredoxin reductase and glutathione reductase.

Björkhem-Bergman L; Jönsson K; Eriksson LC; Olsson JM; Lehmann S; Paul C; Björnstedt M
Article: LEUKEMIA & LYMPHOMA. 2002;43(4):851-858

The expression of cellular retinoid binding proteins in non-APL leukemic cells and its association with retinoid sensitivity.

Lehmann S; Paul C; Törmä H
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2001;66(6):357-364

Effects of arsenic trioxide (As2O3) on leukemic cells from patients with non-M3 acute myelogenous leukemia: studies of cytotoxicity, apoptosis and the pattern of resistance.

Lehmann S; Bengtzen S; Paul A; Christensson B; Paul C
Article: BONE MARROW TRANSPLANTATION. 2000;26(2):187-192

Cardiac systolic function before and after hematopoietic stem cell transplantation.

Lehmann S; Isberg B; Ljungman P; Paul C
Article: BONE MARROW TRANSPLANTATION. 2000;25(9):993-996

N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation.

Ringdén O; Remberger M; Lehmann S; Hentschke P; Mattsson J; Klaesson S; Aschan J
Article: LEUKEMIA RESEARCH. 2000;24(1):19-25

Effects of retinoids on cell toxicity and apoptosis in leukemic blast cells from patients with non-M3 AML.

Lehmann S; Bengtzen S; Broberg U; Paul C
Visa fler

Alla övriga publikationer

Letter: BLOOD ADVANCES. 2021;5(3):787-790

Impact of treatment delay in acute myeloid leukemia revisited.

Juliusson G; Hagberg O; Lazarevic VL; Lehmann S; Höglund M
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2020;189(1):e13-e16

Real-world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged ≥ 60 years.

Österroos A; Eriksson A; Antunovic P; Cammenga J; Deneberg S; Lazarevic V; Lorenz F; Möllgård L; Derolf ÅR; Uggla B; Wennström L; Ölander E; Höglund M; Juliusson G; Lehmann S
Editorial comment: HAEMATOLOGICA. 2020;105(2):249-251

Hypo, Hyper, or Combo: new paradigm for treatment of acute myeloid leukemia in older people.

Juliusson G; Höglund M; Lehmann S
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2020;188(1):187-191

Decreasing early mortality in acute myeloid leukaemia in Sweden 1997-2014: improving performance status is a major contributing factor.

Derolf Å; Juliusson G; Benson L; Fløisand Y; Lazarevic V; Antunovic P; Möllgård L; Lehmann S; Uggla B; Wahlin A; Höglund M; Deneberg S
Letter: BLOOD. 2019;134(18):1558-1561

Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period.

Juliusson G; Hagberg O; Lazarevic VL; Ölander E; Antunovic P; Cammenga J; Wennström L; Möllgård L; Brune M; Jädersten M; Deneberg S; Lehmann S; Derolf ÅR; Höglund M
Letter: LEUKEMIA. 2017;31(6):1457-1459

Early death rates remain high in high-risk APL: update from the Swedish Acute Leukemia Registry 1997-2013.

Lehmann S; Deneberg S; Antunovic P; Rangert-Derolf Å; Garelius H; Lazarevic V; Myhr-Eriksson K; Möllgård L; Uggla B; Wahlin A; Wennström L; Höglund M; Juliusson G
Letter: LEUKEMIA. 2017;31(3):728-731

Prevalence and characteristics of survivors from acute myeloid leukemia in Sweden.

Juliusson G; Abrahamsson J; Lazarevic V; Antunovic P; Derolf Å; Garelius H; Lehmann S; Myhr-Eriksson K; Möllgård L; Uggla B; Wahlin A; Wennström L; Höglund M; Swedish AML Group and the Swedish Childhood Leukem
Letter: BLOOD CANCER JOURNAL. 2016;6(7):e447

An open-label phase I dose-finding study of APR-246 in hematological malignancies.

Deneberg S; Cherif H; Lazarevic V; Andersson P-O; von Euler M; Juliusson G; Lehmann S
Letter: HAEMATOLOGICA. 2015;100(6):e223-e225

High-throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia.

Karimi M; Nilsson C; Dimitriou M; Jansson M; Matsson H; Unneberg P; Lehmann S; Kere J; Hellström-Lindberg E
Review: ALLERGY. 2008;63(7):842-853

Important research questions in allergy and related diseases: nonallergic rhinitis: a GA2LEN paper.

Bousquet J; Fokkens W; Burney P; Durham SR; Bachert C; Akdis CA; Canonica GW; Dahlen S-E; Zuberbier T; Bieber T; Bonini S; Bousquet PJ; Brozek JL; Cardell L-O; Crameri R; Custovic A; Demoly P; van Wijk RG; Gjomarkaj M; Holland C; Howarth P; Humbert M; Johnston SL; Kauffmann F; Kowalski ML; Lambrecht B; Lehmann S; Leynaert B; Lodrup-Carlsen K; Mullol J; Niggemann B; Nizankowska-Mogilnicka E; Papadopoulos N; Passalacqua G; Schünemann HJ; Simon H-U; Todo-Bom A; Toskala E; Valenta R; Wickman M; Zock JP
Meeting abstract: BLOOD. 2007;110(11):161B

Factors affecting long-term survival in non-transplanted acute myeloid leukemia patients

Lof AH; Lehmann S
Meeting abstract: BLOOD. 2007;110(11):133B

Expression of p14ARF in de novo AML with normal karyotype.: Implication on drug resistance and survival

Paul EO; Deneberg S; Lehmann S; Bengtzen S; Nahi H
Meeting abstract: BLOOD. 2004;104(11):501A

Effects of the FLT3 inhibitor PKC 412 in combination with cytostatic drugs in vitro in acute myeloid leukemia.

Möllgård L; Bengtzen S; Fioretos T; Andersson A; Paul C; Lehmann S
Corrigendum: BIOCHEMICAL PHARMACOLOGY. 2002;64(1):159

Drug-resistant human lung cancer cells are more sensitive to selenium cytotoxicity -: Effects on thioredoxin reductase and glutathione reductase (vol 63, pg 1875, 2002)

Björkhem-Bergman L; Jönsson K; Eriksson LC; Olsson JM; Lehmann S; Paul C; Björnstedt M
Published paper: CLINICAL CANCER RESEARCH. 2001;7(2):367-373

Retinoid receptor expression and its correlation to retinoid sensitivity in non-M3 acute myeloid leukemia blast cells.

Lehmann S; Paul C; Törmä H
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2000;108(1):198-199

The retinoic acid syndrome in non-M3 acute myeloid leukaemia: a case report.

Lehmann S; Paul C
Review: LAKARTIDNINGEN. 1999;96(50):5626-5628

[Arsenic efficient in acute promyelocytic leukemia].

Lehmann S; Paul C

Anställningar

Anknuten till Forskning, Medicin, Huddinge, Karolinska Institutet, 2023-2026

Examina och utbildning

Docent, Inriktning: hematologi, Karolinska Institutet, 2010
MEDICINE DOKTORSEXAMEN, Institutionen för medicin, Huddinge, Karolinska Institutet, 2002
Läkarexamen, Karolinska Institutet, 1992

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI